Stock Events

Stock Events

Replimune Group 

€2.41
52
-€0.17-6.51% Tuesday 19:55

Statistics

Day High
2.58
Day Low
2.16
52W High
10.6
52W Low
1.29
Volume
1,736
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q4 2025
Next
-0.65
-0.62
-0.59
-0.56
Expected EPS
-0.55714163523
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7R8.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. has a broad portfolio in oncology, including immuno-oncology treatments that compete with Replimune's cancer therapies.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. offers Keytruda, a leading immunotherapy drug, which competes in the broader cancer treatment market against Replimune's products.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb has a strong lineup of cancer drugs, including immunotherapies that rival Replimune's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. is involved in the development of cancer therapies, including cell therapies, which can be seen as competitive to Replimune's viral-based treatments.
Novavax
NVAX
Mkt Cap1.32B
Novavax, Inc., while primarily known for vaccines, is exploring cancer vaccine candidates that could potentially compete with Replimune's viral immunotherapies.
Iovance Biotherapeutics
IOVA
Mkt Cap1.52B
Iovance Biotherapeutics, Inc. specializes in tumor-infiltrating lymphocyte (TIL) therapies for cancer, offering a different but competitive approach to Replimune's methods.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diverse oncology portfolio, including investments in immunotherapies that compete with the innovative cancer treatments developed by Replimune.

About

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Show more...
CEO
Dr. Sushil Patel Ph.D.
Employees
479
Country
United States
ISIN
US76029N1063

Listings

STU
DE
7R8.STU
MU
DE
7R8.MU
F
DE
7R8.F
XNAS
US
REPL

0 Comments

Share your thoughts

FAQ

What is Replimune Group stock price today?▼
The current price of 7R8.STU is €2.41 EUR — it has decreased by -6.51% in the past 24 hours. Watch Replimune Group stock price performance more closely on the chart.
What is Replimune Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Replimune Group stocks are traded under the ticker 7R8.STU.
Is Replimune Group stock price growing?▼
7R8.STU stock has risen by +18.59% compared to the previous week, the month change is a -66.04% fall, over the last year Replimune Group has showed a -70.78% decrease.
When is the next Replimune Group earnings date?▼
Replimune Group is going to release the next earnings report on May 14, 2026.
What were Replimune Group earnings last quarter?▼
7R8.STU earnings for the last quarter are -0.65 EUR per share, whereas the estimation was -0.65 EUR resulting in a -0.9% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Replimune Group have?▼
As of May 06, 2026, the company has 479 employees.
In which sector is Replimune Group located?▼
Replimune Group operates in the Health & Wellness sector.
When did Replimune Group complete a stock split?▼
Replimune Group has not had any recent stock splits.
Where is Replimune Group headquartered?▼
Replimune Group is headquartered in Woburn, United States.